Key result
Early mitoxantrone links to temporary LVEF decline and diastolic dysfunction in ~22% of patients.
Why the study?
Does early mitoxantrone treatment cause cardiotoxicity in patients with secondary progressive multiple sclerosis?
Population
18 patients with secondary progressive multiple sclerosis prospectively assessed at a single institution…
Design
Case_series
Follow-up
2 years
Authors
Loading...
Potential early cardiotoxicity in mitoxantrone-treated SPMS; hypothesis-generating and should not yet change practice.
Observational (n=18)
No
Does early mitoxantrone treatment cause cardiotoxicity in patients with secondary progressive multiple sclerosis?
Mitoxantrone can induce early, temporary cardiotoxicity (LVEF decrease and diastolic dysfunction) even after just one or two doses, highlighting the need for early and regular echocardiographic monitoring.
Paul et al. (2007) conducted an observational in Secondary progressive multiple sclerosis (n=18). Mitoxantrone was evaluated on Temporary and considerable decrease in LVEF and diastolic dysfunction. Among 18 patients with secondary progressive multiple sclerosis, 22.2% experienced a temporary and considerable decrease in LVEF and diastolic dysfunction after only one or two doses of mitoxantrone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: